Clinical Trials

Both MDMA and psilocybin are in the process of being researched and approved for therapeutic use to treat a number of conditions, including PTSD, depression, anxiety, and addiction. In addition to supporting regulatory change via our clinical advisory board, Numinus is conducting clinical trials with both substances, and preparing for the eventual roll-out of these therapies to the general public.

Hands in water

Compassionate Access Trial


Numinus has partnered with MAPS for a single-arm, open-label, compassionate access trial for MDMA-assisted therapy for PTSD.

Rock texture

Compassionate Access Trial

Psilocybin for Substance Use Disorder

Numinus has partnered with Syreon Corporation to pursue a single-arm, open-label compassionate access trial of Psilocybin-Research Intervention with Motivational Enhancement (PRIME) for substance use disorders.

Clinical Trial News

Get notified when these treatments become available.

Join our early interest list for MDMA and Psilocybin Assisted Psychotherapy and we’ll keep you updated on progress.